Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $17.08.

A number of brokerages have recently weighed in on CERT. Robert W. Baird dropped their price target on Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. KeyCorp dropped their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Barclays dropped their price objective on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday. JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th.

Certara Trading Up 0.1 %

Shares of CERT stock opened at $11.22 on Thursday. Certara has a fifty-two week low of $10.35 and a fifty-two week high of $19.87. The stock has a market cap of $1.80 billion, a P/E ratio of -28.77, a P/E/G ratio of 5.40 and a beta of 1.49. The business has a fifty day simple moving average of $11.67 and a 200-day simple moving average of $14.48. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The firm had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. During the same quarter in the prior year, the business earned $0.10 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, analysts forecast that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently modified their holdings of the company. Sei Investments Co. lifted its stake in shares of Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock valued at $12,793,000 after purchasing an additional 79,013 shares in the last quarter. Geneva Capital Management LLC lifted its position in Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after acquiring an additional 579,349 shares in the last quarter. Wasatch Advisors LP lifted its position in Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares in the last quarter. Motley Fool Asset Management LLC lifted its position in Certara by 94.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company’s stock worth $1,731,000 after acquiring an additional 46,897 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its position in Certara by 27.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock worth $9,231,000 after acquiring an additional 110,636 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.